In a remarkable regulatory turnaround, the U.S. Food and Drug Administration has officially granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), an engineered, herpes-based oncolytic viral therapy developed by biotechnology firm Replimune Group. Indicated for adult patients suffering from unresectable or advanced cutaneous melanoma whose cancer has progressed after standard anti-PD-1 immunotherapy, the green light offers a critical new lifespan extension for patients facing severe treatment resistance.
The decision marks a historic victory for Woburn, Massachusetts-based Replimune. After suffering two previous regulatory rejections, in July 2025 and April 2026, due to intense debates surrounding trial design and data interpretability, a recent 10-to-3 vote by an FDA advisory committee paved the way for the company's first commercial product launch. For oncologists treating patients who have exhausted standard immunotherapy options, Tudriqev represents the first new mechanism of action in years.
The Biological Mechanism | A Targeted One-Two Punch
Tudriqev belongs to an emerging, highly specialized class of cancer treatments known as oncolytic viral immunotherapies. Derived from a genetically modified strain of the herpes simplex virus type 1 (HSV-1), the therapy is injected directly into visible melanoma lesions once every two weeks. Once inside, the attenuated virus replicates rapidly inside tumor cells, causing them to rupture and die from the inside out.
This direct tumor-killing effect is only half the story. Crucially, as the target cancer cells burst open, they release tumor-specific antigens directly into the surrounding tissue. This secondary effect acts as an internal beacon, awakening the patient's immune system to recognize, track down, and attack remaining untreated metastatic tumors throughout the body. The mechanism effectively turns a localized injection into a systemic immune response, a property that distinguishes oncolytic viruses from conventional chemotherapy or targeted radiation.
To maximize this systemic immune wave, Tudriqev is administered in tandem with Bristol Myers Squibb's heavy-hitting PD-1 checkpoint inhibitor Opdivo (nivolumab). The virus exposes the tumor antigens. Opdivo removes the brakes on the immune system. Together, they create a one-two punch that neither drug could deliver alone.
The Clinical Data | The IGNYTE Trial Blueprint
The FDA's accelerated approval is built upon data from the pivotal Phase 1/2 IGNYTE clinical trial, which evaluated the combination therapy in 140 patients with advanced stage IIIB to IV cutaneous melanoma who had stopped responding to prior PD-1 blocking drugs. Among the 91 patients with non-injected baseline lesions, the efficacy-evaluable population, the combination produced a 24.2% objective response rate with a median duration of response of 14.1 months.
These numbers require context to appreciate. Patients in the IGNYTE trial had already failed the standard of care. Their tumors had progressed through anti-PD-1 therapy, the most effective immunotherapy class available. In this population, median survival historically drops sharply, and alternative treatment options are virtually non-existent. A 24.2% response rate with responses lasting over a year is not merely statistically significant. It is clinically meaningful for patients who had run out of options.
The administration protocol calls for intratumoral injection every two weeks for up to eight total doses. A mandatory confirmatory trial, IGNYTE-3, is required to verify long-term survival benefits and convert the accelerated approval to full, permanent status. Replimune must demonstrate that the response rates observed in the single-arm trial translate into genuine overall survival improvements in a randomized controlled setting.
Overcoming Regulatory Pushback | From Rejection to Approval
The path to approval was far from smooth. Internal reviewers at the FDA initially expressed deep skepticism regarding the single-arm trial design of IGNYTE, arguing that without a control group, it was difficult to isolate Tudriqev's distinct contribution from Opdivo alone. Regulators also questioned whether an injection localized to one tumor site could reliably generate a system-wide antitumor response, a biological claim that, if unsubstantiated, would undermine the therapy's entire value proposition.
However, external oncology experts on the advisory committee strongly advocated for the drug. They noted that an objective response rate of 24.2% in an aggressive, post-immunotherapy patient population far surpasses historical benchmarks, where median survival drops sharply and alternative treatment options are virtually non-existent. The 10-to-3 vote reflected a clear consensus that the unmet medical need outweighed the methodological limitations of the trial design.
While Replimune must complete its ongoing randomized, confirmatory Phase 3 trial to secure full, permanent approval status, the accelerated rollout provides oncologists with an immediate, potent weapon against refractory skin cancers. As commercial distribution begins, Tudriqev stands as a compelling proof-of-concept for harnessing engineered viruses to defeat the body's most stubborn malignancies, and a vindication for the oncolytic viral therapy field, which has spent decades moving from laboratory curiosity to approved medicine.